Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2
Recruiting
Observational Study
BRCA1 and/or BRCA2 Variant Carriers
Ovarian Carcinoma
Fallopian Tube Carcinoma
Peritoneal Carcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 20 and older
- Sex
- Female
- Study type
- Observational
- Participants needed
- 600 (estimated)
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To determine the incidence and risk factors in the development of ovarian, fallopian tube, and peritoneal cancers in Japanese women carrying Breast Cancer Susceptibility Gene (BRCA)1/2 variants.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Women carrying BRCA1/2 variants (those with either BRCA1 or BRCA2 variants, or those carrying both variants) and women carrying a variant of uncertain significance (VUS).
2. Women who have received sufficient genetic counseling at any medical institution, prior to enrollment …
Contacts